A Primary Approach to Cancers of Unknown Primary
Open Access
- 2 May 2013
- journal article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 105 (11) , 759-761
Abstract
Most solid tumors are diagnosed in their organ of origin; however, approximately 20% of patients will present with a tumor identified in one or more metastatic sites. In the overwhelming majority of cases, a clinical history, physical examination, laboratory tests, functional and radiographic imaging (positron emission tomography/computed tomography), and histologic assessment will disclose the primary site, enabling site-directed chemotherapy. Yet, again, in approximately 20% of cases, the primary site eludes determination, even after examination of broad panels of immunohistochemical assays. These cancers of unknown primary organ (CUP), defined as metastatic cancers whose anatomic origin is clinically not detectable even after a thorough diagnostic evaluation, represent a heterogeneous group of malignancies and account for approximately 4% of cancer diagnoses ( 1 , 2 ). Interestingly, in our experience, even after postmortem examination, 20% of CUPs, or about 1% of all cancers, are never anatomically defined. Although these cancers present as metastases and represent a spectrum of biological behavior, oncologists have stratified them into favorable (approximately 20%) and poor (approximately 80%) prognostic groups based on such factors as clinical presentation, host factors, tumor histology, number and location of metastatic sites, and their sensitivity to chemoradiation treatment ( 1–3 ). In general, patients with CUP have an overall survival of 6 to 9 months, although the favorable prognostic group may have a median survival of nearly 36 months.Keywords
This publication has 20 references indexed in Scilit:
- Cancer of unknown primary siteThe Lancet, 2012
- Immunohistochemical Profile for Unknown Primary AdenocarcinomaPLOS ONE, 2012
- Cancers of unknown primary origin: current perspectives and future therapeutic strategiesJournal of Translational Medicine, 2012
- Carcinoma of Unknown Primary: Focused EvaluationJournal of the National Comprehensive Cancer Network, 2011
- Gene Expression Analysis and Immunohistochemistry in Evaluation of Cancer of Unknown Primary: Time for a Patient-Centered ApproachJournal of the National Comprehensive Cancer Network, 2011
- Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomesAnnals of Oncology, 2011
- Molecular Profiling in Unknown Primary Cancer: Accuracy of Tissue of Origin PredictionThe Oncologist, 2010
- Diagnosis of Metastatic Neoplasms: Molecular Approaches for Identification of Tissue of OriginArchives of Pathology & Laboratory Medicine, 2010
- Molecular Classification of Unknown Primary CancerSeminars in Oncology, 2009
- A Quantitative Reverse Transcriptase-Polymerase Chain Reaction Assay to Identify Metastatic Carcinoma Tissue of OriginThe Journal of Molecular Diagnostics, 2006